Sirona Biochem Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: CA82967M1005
CAD
0.06
-0.13 (-67.84%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Sirona Biochem Corp. stock-summary
stock-summary
Sirona Biochem Corp.
Pharmaceuticals: Major
Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.
Company Coordinates stock-summary
Company Details
Sirona Biochem Corp. (c/o WeWork), 595 Burrard St. VANCOUVER BC : V7X 1L3
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Howard Verrico
Chairman of the Board, Chief Executive Officer, Founder, Secretary
Mr. Christopher Hopton
Chief Financial Officer, Director
Dr. Geraldine Deliencourt-Godefroy
Chief Scientific Officer, Director
Dr. Alex Marazzi
Independent Director
Mr. Jason Tian
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jul 2024)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

CAD 16 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.95

stock-summary
Return on Equity

76.97%

stock-summary
Price to Book

-4.57